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ABSTRACT 
Development of obsessive-compulsive symptoms during clozapine treatment in schizophren-
ics has been noted in few reports from west. In our cases, three schizophrenic patients resistant to 
typical antipsychotics developed obsessive-compulsive symptoms during clozapine treatment. Since 
clozapine is a potent 5-HT2 receptor blocker, role of serotonergic systems in the development of 
obsessive-compulsive symptoms may be considered. It may be prudent to be vigilant for the 
emergence of obsessive-compulsive symptoms in all patients treated with clozapine. 
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Major adverse effects associated with 
clozapine treatment are sedation, tachycardia, 
constipation, dizziness, hypotension, hyperther-
mia, sialorrhoea, seizures and agranulocytosis 
(Kammen & Marder, 1995) but there are occa-
sional reports of development of obsessive-
compulsive symptoms during clozapine treat-
ment in schizophrenic patients (Patel, 1992; 
Cassady & Thaker, 1992; Patel & Tandon, 
1993). In a short span of two years, out of nearly 
hundred patients treated with clozapine, we 
encountered three schizophrenic patients who 
developed obsessive-compulsive symptoms. 
CASE -1 
Ms. A, a 20 year old girl with treatment 
refractory paranoid schizophrenia, responded 
well to treatment with clozapine (300 mg/day) 
with improvement of both positive and 
negative symptoms. After four months of 
treatment with clozapine, she developed 
obsessive-compulsive symptoms, predomi-
nantly compulsive in form of repetitive 
checking and cleaning rituals. It was decided 
not to discontinue clozapine as her 
schizophrenic symptoms, which were in 
remission with clozapine, had not responded to 
adequate trials of typical antipsychotics and 
even risperidone in the past and obsessive-
compulsive symptoms were not servere enough 
to hamper her day to day functioning. 
CASE- 2 
Mr. B, a 32 year old man was suffering 
from paranoid schizophrenia from the age of 
20 year and was resistant to various traditional 
antipsychotics. He was placed on clozapine and 
his dosage gradually increased to 450 mg/day 
to which he responded. When the dosage was 
reduced to 400 mg/day, the patient developed 
obsessive doubts which he described as repeti-
tive, intrusive, irrational, and caused marked 
anxiety. On reverting to earlier dosage (450 
mg/day) his obsessive doubts partially 
ameliorated. However, he still experiences 
obsessive doubts but prefers them to 
reduced-dosage of clozapine because he feels 
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that he was never as good earlier. 
CASE- 3 
Mr. C, a 32 year old man diagnosed as a 
case of paranoid schizophrenia for six years was 
treatment resistant. Clozapine was started and 
gradually increased to 400 mg/day. After one 
year of treatment he developed severe obses-
sive-compulsive symptoms due to which cloza-
pine had to stopped and he was given 
tablet trifluoperazine (7.5 mg/day). Interestingly, 
his resistant schizophrenic symptoms 
responded to trifluoperazine and patient is more 
or less symptom free. 
DISCUSSION 
Patil (1992) first reported the develop-
ment of transient obsessive-compulsive symp-
toms in two schizophrenic patients successfully 
treated with clozapine. Patel & Tandon (1993) 
also observed the same phenomenon; however, 
these symptoms were not transient and 
fluoxetine successfully treated the obsessive 
compulsive symptoms without compromising 
the effectiveness of clozapine. Cassady & 
Thaker (1993) have also reported usefulness 
of fluoxetine in such patients. However, 
Steingard et al. (1993) found that obsessive-
compulsive symptoms during clozapine treat-
ment tended to be persistent and response to 
fluoxetine was variable. Torenetal. (1995) have 
reported emergence of obsessive-compulsive 
symptoms in a drug-naive eight year old boy 
with schizophrenia treated with another 
atypical antipsychotic-clothiapine. However, in 
treatment refractory OCD, clozapine 
monotherapy resulted in neither improvement 
nor worsening of obsessive-compulsive 
symptoms (Mc Dougle, 1995). 
In our cases, obsessive-compulsive 
symptoms during clozapine treatment of schizo-
phrenics were variable in presentation and 
course. Case 1 had predominantly compulsive 
symptoms which were persistent with 
clozapine treatment. Case 2 had only obses-
sive doubts which reduced with clozapine dose 
escalation. Case 3 had severe obsessive-com-
pulsive symptoms requiring discontinuation of 
clozapine. We did not use fluoxetine in these 
cases because some schizophrenic patients 
with obsessive-compulsive features become 
more psychotic and disorganised following the 
addition of serotonin reuptake inhibitor 
(Lindenmayer et al., 1990). In addition, it has 
been reported that fluoxetine can lead to marked 
increase in serum levels of clozapine (Kammen 
& Marder, 1995) which may indicate that the 
combination is not safe. 
Clozapine is a potent 5-HT antagonist 
and the data suggest that 5-HT blockade may 
underlie the development of obsessive-compul-
sive symptoms in the course of clozapine treat-
ment. "Perhaps, etiologically schizophrenia has 
several subsets and one of them represents a 
serotonergic neurotransmitter system in the 
brain where too little serotonin causes 
obsessive-compulsive symptoms and too much 
causes schizophrenic symptoms. It is possible 
that the mechanism of action of clozapine is its 
anti-serotonergic property. It is also possible that 
the 30% of treatment-resistant patients who 
respond favourably to clozapine represent this 
subset of schizophrenia" (Patil, 1992). 
In the light of still limited knowledge in 
this field and the multiplicity of central effects 
of clozapine, we feel that such speculation is 
premature. Nevertheless, we believe that 
emergence of obsessive-compulsive symptoms 
during treatment with clozapine may be more 
common than reported so far and it is 
worthwhile to routinely .check for such 
symptoms or else one can miscontrue these as 
worsening of schizophrenia. 
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